Key Developments: Array Biopharma Inc (ARRY.OQ)

ARRY.OQ on NASDAQ Stock Exchange Global Market

4.86USD
19 Dec 2014
Price Change (% chg)

$0.06 (+1.25%)
Prev Close
$4.80
Open
$4.78
Day's High
$4.93
Day's Low
$4.76
Volume
2,624,730
Avg. Vol
639,367
52-wk High
$5.63
52-wk Low
$2.98

Search Stocks

Latest Key Developments (Source: Significant Developments)

Array BioPharm Inc announces termination and asset transfer agreement - Form 8-K
Wednesday, 3 Dec 2014 04:06pm EST 

Array BioPharm Inc:Entered into termination and asset transfer agreement dated Nov. 26, 2014 with Novartis Pharma AG and Novartis International Pharmaceutical Ltd.Under Novartis Agreement, Array, Novartis and NIP agreed to terms pursuant to which Array will regain all development and commercialization rights to binimetinib, MEK oncology program that Array had previously licensed to NIP under license agreement dated April 19, 2010.When transactions contemplated by Novartis agreement become effective, existing license agreement will terminate.  Full Article

Array Biopharma Inc gives Q2 2015 loss outlook; revenue outlook below analysts' estimates - Conference Call
Tuesday, 4 Nov 2014 09:00am EST 

Array Biopharma Inc:Expects Q2 2015 revenue to $7 mln and a slightly reduced loss per share to $0.20.Q2 2015 revenue of $8 mln, EPS of $(0.20) - Thomson Reuters I/B/E/S.  Full Article

Array Biopharma Inc gives Q1 2015 guidance below analysts' estimates - Conference call
Tuesday, 12 Aug 2014 09:00am EDT 

Array Biopharma Inc:Sees Q1 2015 revenue and loss per share (EPS) to be similar to Q4 2014.Reported revenue of $6.01 mln and EPS of $(0.22) in Q4 2014.Q1 2015 revenue of $10.06 mln and EPS of $(0.21) - Thomson Reuters I/B/E/S.  Full Article

Array BioPharma announces drug discovery collaboration agreement with Biogen Idec
Wednesday, 28 May 2014 09:00am EDT 

Array BioPharma Inc:Says collaboration agreement with Biogen Idec for discovery and development of inhibitors targeting a novel kinase for the treatment of autoimmune disorders.Biogen will be responsible for all aspects of clinical development and commercialization.Agreement includes research funding for three years, various milestone payments payable upon achievement of certain development and commercial milestones, and royalties to Array.  Full Article

Array BioPharma Inc reaffirms FY 2014 EPS outlook; lowers FY 2014 revenue outlook; gives Q4 2014 outlook - Conference Call
Tuesday, 29 Apr 2014 09:00am EDT 

Array BioPharma Inc:Says there is no change to the FY 2014 guidance for loss per share, although the revenue guidance is several mln lower.Expect Q4 2014 revenue and loss per share to be pretty similar to Q3 2014.Reported revenue of $7.77 mln, EPS of $(0.20) in Q3 2014.FY 2014 revenue of $49.80 mln, EPS of $(0.69) - Thomson Reuters I/B/E/S.Q4 2014 revenue of $11.47 mln, EPS of $(0.21) - Thomson Reuters I/B/E/S.  Full Article

Oncothyreon Inc and Array BioPharma announce initiation of phase 1b trial of ONT-380 in combination with TDM-1 in patients with metastatic HER2+ breast cancer
Thursday, 20 Feb 2014 08:00am EST 

Oncothyreon Inc:Says the company and Array BioPharma Inc initiation of a Phase 1b trial of ONT-380 (ARRY-380) in combination with Kadcyla (ado-trastuzumab emtansine or TDM-1) in patients with metastatic HER2+ breast cancer.ONT-380 is an orally active, reversible and selective small-molecule HER2 inhibitor invented by Array and being developed by Oncothyreon in collaboration with Array.The trial (ClinicalTrials.gov Identifier NCT01983501) is a dose-escalation study in up to 48 patients who have been previously treated with Herceptin (trastuzumab) and a taxane for metastatic breast cancer.Primary objective is to determine the maximum-tolerated and/or recommended Phase 2 dose (MTD/RP2D) of ONT-380 in combination with the approved dose of Kadcyla.Secondary objectives include an evaluation of the safety and preliminary anti-tumor activity of the combination.Following determination of the MTD/RP2D, the study includes an expansion arm at the MTD/RP2D as well as an optional second expansion arm in patients with central nervous system metastases.  Full Article

Array Biopharma Inc reaffirms FY 2014 guidance and gives Q3 2014 EPS guidance; revenue guidance below analysts' estimates - Conference Call
Tuesday, 4 Feb 2014 09:00am EST 

Array Biopharma Inc:Says no change to the FY 2014 guidance.Expects Q3 2014 revenue of $8 mln.Expects Q3 2014 loss per share of about $0.21.Q3 2014 revenue of $11.11 mln and EPS of $-0.20 - Thomson Reuters I/B/E/S.  Full Article

Array Biopharma Inc Announces Resignation Of President-Form 8-K
Thursday, 21 Nov 2013 08:05am EST 

Array Biopharma Inc reported in its Form 8-K that on November 15, 2013, Kevin Koch, Ph.D., resigned as President and Chief Science Officer of Array, effective November 29, 2013. Dr. Koch resigned to pursue other professional opportunities and his resignation did not arise from any disagreement on any matter relating to the Array’s operations, policies or practices.  Full Article

Array Biopharma Inc Raises FY 2014 Guidance - Conference Call
Thursday, 31 Oct 2013 09:00am EDT 

Array Biopharma Inc announced that for fiscal 2014, it expects revenue of $49 million and loss per share at $0.69, which is an improvement of $0.03 from last update.  Full Article

Array Biopharma Inc Issues FY 2014 Guidance-Conference Call
Thursday, 8 Aug 2013 09:00am EDT 

Array Biopharma Inc announced that for fiscal 2014, it expects revenue to be approximately $48 million and loss per share $0.72.  Full Article

BUZZ-Array BioPharma Inc: Eight-month high on Novartis deal

** Drug developer's shares rise as much as 24 pct to eight-month high of $4.84, the biggest intra-day jump in four-and-half years

Search Stocks